Semaglutide and Cardiovascular Outcomes in Obesity | NEJM

Name: Semaglutide and Cardiovascular Outcomes in Obesity | NEJM
Uploaded: 2023-12-14T00:00:00
Description: Semaglutide reduces cardiovascular events in overweight/obese patients without diabetes. Trial shows 6.5% vs 8.0% event rate vs placebo over 40 months.

1 min read

Medical Disclaimer: This content is for educational purposes only and is not medical advice. Consult a qualified professional for medical decisions.